BioSpace News Archive

Recursion, a digital biology company industrializing drug discovery, released its open-source RxRx19 dataset, which is the first human cellular morphological dataset of SARS-CoV-2 (COVID-19).

-Appoints Sol J. Barer, Ph.D. as Chairman of the Board - Appoints Suzanne Bruhn, Ph.D. and Joseph Miller as Directors to the Board ROCKVILLE, Md., April 24, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, today announced that Dr. Sol J. Barer has been appointed as the Chairman of the Board as Dr. Simon Pedder steps down as Executive Chairman

Leica Biosystems, the global leader in pathology workflow solutions, today announced it has received additional notification from the U.S. Food & Drug Administration (FDA) about its intention to exercise enforcement discretion when the Aperio WebViewer, a web-based viewing software within Aperio eSlide Manager , is used for remo

A new study by the company titled ‘MRI Guided & Focused Ultrasound Devices Market: Global Industry Analysis 2013-2017 and Forecast 2018-2026’, has listed out the key points being considered by MRI Guided & Focused Ultrasound Devices companies to emerge and stay sustainably profitable in the long run in the MRI Guided & Focused Ultrasound Devices market.

Infection preventionists will leverage Real Time Medical Systems’ interventional analytics and Sensiva Health’s COVID-19 antibody testing to advance infection prevention at long-term care facilities in the Southeast U.S.

This week, Methodist Le Bonheur Healthcare announced it is participating in Mayo Clinic’s Expanded Access Protocol for Convalescent Plasma Program for treatment of patients with COVID-19.

Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported consolidated financial and operating results for the year ended December 31, 2019.

Quanterix Corporation (NASDAQ: QTRX), a company digitizing analysis to advance the science of precision health, today announced a call for proposals for the Simoa® Success Grant Program.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or “the Company”) today announced the closing of the Company’s previously announced underwritten public offering of 210,833,334 shares of common stock (or common stock equivalents in lieu thereof) at an effective public offering price of $0.15 per share of common stock

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it plans to release its financial results for the first quarter of 2020 after market close on Thursday, May 14, 2020.